ATF2 (Ab-73 or 55) Antibody

What is ATF2 and why is it significant in cellular research?

ATF2 (Activating Transcription Factor 2) is a member of the ATF/CREB family of leucine zipper proteins that binds to both AP-1 and CRE DNA response elements . It plays crucial roles in the transcriptional regulation of genes involved in cytokines, cell cycle control, and apoptosis . ATF2 is particularly abundant in the brain and is considered an important substrate of signals upstream of the activation of genes associated with neuronal growth and differentiation . Research has also linked ATF2 expression to depression in humans . Additionally, recent studies have identified ATF2 as a potential tumor suppressor in colorectal cancer, where its loss promotes tumor invasion through upregulation of the cancer driver TROP2 .

What are the primary applications for ATF2 (Ab-73 or 55) antibody?

The ATF2 (Ab-73 or 55) antibody is used in multiple experimental techniques:

• Western Blotting: Used at dilutions of 1:500-1:1000

• Immunohistochemistry (IHC): Applied for both formalin-fixed, paraffin-embedded sections at 1:50-1:100 dilutions

• Enzyme-Linked Immunosorbent Assay (ELISA)

• Immunofluorescence (IF)

These applications make this antibody versatile for detecting ATF2 expression and phosphorylation status in various experimental settings, particularly when investigating signaling pathways involving ATF2 activation.

What is the recommended storage and handling procedure for maintaining antibody efficacy?

For optimal performance of the ATF2 (Ab-73 or 55) antibody:

• Storage temperature: Maintain at -20°C for long-term storage

• Shipping conditions: The antibody is typically shipped on wet ice

• Aliquoting: For antibodies stored in glycerol (such as the ATF2 Ser490,498 antibody), aliquoting may not be necessary as samples can be taken without freeze/thaw cycles

• Stability: When properly stored, the antibody maintains stability for at least 1 year at -20°C

• Buffer composition: Typically suspended in buffered aqueous solution . Some variants are provided in 10 mM HEPES (pH 7.5), 150 mM NaCl, 100 μg per ml BSA and 50% glycerol

Avoiding repeated freeze-thaw cycles is recommended to preserve antibody performance and specificity.

How does the ATF2 (Ab-73 or 55) antibody differ from other ATF2 antibodies?

The ATF2 (Ab-73 or 55) antibody specifically recognizes the phosphorylated form of ATF2 at threonine 73 (also referred to as threonine 55 in some splice variants) . This distinguishes it from:

• Antibodies targeting other phosphorylation sites:

  • ATF2 (pThr51/pThr69) antibodies

  • ATF2 (pSer44/pSer62) antibodies

  • ATF2 (pThr53/pThr71) antibodies

  • ATF2 (Ser490/498) antibodies

• Antibodies recognizing specific regions of ATF2:

  • ATF2 (AA 1-190) antibodies

  • ATF2 (AA 93-450) antibodies

  • ATF2 (C-Term) antibodies

The phospho-specificity of the Ab-73/55 antibody makes it valuable for studying ATF2 activation status in response to various cellular stimuli, as phosphorylation is a key regulatory mechanism for ATF2 function .

How can I validate the specificity of ATF2 (Ab-73 or 55) antibody in my experimental system?

To rigorously validate the specificity of the ATF2 (Ab-73 or 55) antibody in your experimental system:

• Phosphatase treatment control: Treat cell lysates with lambda phosphatase to remove phosphorylation and confirm loss of antibody binding.

• Stimulation experiments: Compare unstimulated cells with those treated with known ATF2 phosphorylation inducers (e.g., UV irradiation, inflammatory cytokines) .

• siRNA or CRISPR knockout validation: Perform ATF2 knockdown or knockout to confirm specificity, as demonstrated in studies showing that knockdown of ATF2 abolished tolfenamic acid (TA)-induced ATF3 expression .

• Peptide competition assay: Pre-incubate the antibody with phospho-peptide immunogens containing the T-P-T(p)-R-F sequence to block specific binding .

• Cross-reactivity assessment: Test the antibody across multiple species (human, mouse, rat, monkey) as specified in the product data to confirm the expected pattern of reactivity.

The antibody has been purified using affinity chromatography with epitope-specific phosphopeptide, with non-phospho specific antibodies removed through additional chromatography , enhancing its specificity for the phosphorylated form.

What are the best experimental conditions for detecting ATF2 phosphorylation dynamics?

For optimal detection of ATF2 phosphorylation dynamics:

• Stimulation protocols:

  • UV irradiation: Known to stimulate ATF2 transcriptional activity

  • Inflammatory cytokines: Activate stress-induced ATF2-dependent transcription

  • Tolfenamic acid (TA): Increases ATF2 phosphorylation via p38MAPK, ERK, and JNK pathways

• Time course considerations:

  • ATF2 phosphorylation occurs rapidly after stimulation

  • Monitor both early (5-30 minutes) and late (1-6 hours) time points to capture the complete phosphorylation profile

  • Tolfenamic acid treatment shows a sequential process where ATF2 phosphorylation precedes ATF3 transcription

• Cell lysis conditions:

  • Use phosphatase inhibitors (sodium fluoride, sodium orthovanadate, β-glycerophosphate) in all buffers

  • Maintain samples at cold temperatures during processing

  • Consider rapid sample denaturation to preserve phosphorylation status

• Kinase pathway inhibitors as controls:

  • p38 MAPK inhibitors

  • JNK inhibitors

  • ERK pathway inhibitors

  These inhibitors can help identify which specific pathways mediate ATF2 phosphorylation in your experimental context, as studies have shown these pathways regulate ATF2 phosphorylation in response to stimuli like tolfenamic acid .

How can I distinguish between different phosphorylated forms of ATF2 in my research?

Distinguishing between different phosphorylated forms of ATF2 requires strategic experimental design:

• Antibody selection panel:

  • Use antibodies specific to different phosphorylation sites:

    • ATF2 (Ab-73/55) for Thr73/55 phosphorylation

    • Anti-ATF2 (pThr51/pThr69) for those specific residues

    • Anti-ATF2 (pSer490/498) for C-terminal phosphorylation

• Phosphorylation site mutant constructs:

  • Generate threonine-to-alanine mutants (T73A, T51A, T69A, etc.)

  • Express in cells to identify functional consequences of specific phosphorylation events

• Kinase-specific contexts:

  • p38 MAPK primarily phosphorylates Thr69 and Thr71

  • JNK phosphorylates Thr69, Thr71, and potentially Ser90

  • ERK may target different sites

  • Use kinase inhibitors to block specific pathways and observe which phosphorylation sites are affected

• Two-dimensional phosphorylation analysis:

  • Combine immunoprecipitation with phospho-specific antibodies

  • Follow with Western blotting using antibodies to other phosphorylation sites

  • This approach can reveal patterns of co-occurrence of different phosphorylation events

Research has shown that phosphorylation of ATF2 is regulated by multiple MAPK pathways, including p38MAPK, ERK, and JNK, which subsequently modulate downstream gene expression .

What approaches can resolve contradictory results when studying ATF2 functions in different cellular contexts?

When encountering contradictory results regarding ATF2 functions across different cellular contexts:

• Cell type-specific expression analysis:

  • Quantify baseline ATF2 expression levels across cell types

  • ATF2 is particularly abundant in brain tissue compared to other tissues

  • Map expression of ATF2 interacting partners and modulators

• Isoform-specific investigation:

  • The antibody recognizes both the ~74 kDa ATF2 protein and a ~54 kDa splice form

  • Design experiments to distinguish between the functions of different ATF2 isoforms

  • Use isoform-specific siRNAs where possible

• Context-dependent roles assessment:

  • ATF2 has exhibited both oncogenic and tumor-suppressive functions

  • In colorectal cancer, ATF2 loss promotes tumor invasion via upregulation of TROP2

  • Compare ATF2 functions in normal vs. transformed cells from the same tissue origin

• Signaling network mapping:

  • Create pathway-specific activation profiles

  • For example, tolfenamic acid leads to increases in phospho-p38 MAPK, JNK, and ERK levels before ATF2 activation

  • Use inhibitors of these pathways to dissect their relative contributions

• Subcellular localization tracking:

  • Monitor ATF2 translocation between cytoplasm and nucleus

  • Correlate localization with functional outcomes and phosphorylation status

A comprehensive approach incorporating these strategies can help reconcile apparently contradictory roles of ATF2, such as its context-dependent functions in cancer biology where it can act as both a tumor promoter and suppressor depending on the cellular context .

What are the technical considerations for multiplexing ATF2 phosphorylation detection with other signaling markers?

For effective multiplexing of ATF2 phosphorylation detection with other signaling markers:

• Antibody compatibility matrix:

  Detection Method	Primary Antibody Hosts	Secondary Detection System	Considerations
  Fluorescence multiplexing	ATF2 (rabbit) with other markers (mouse/goat)	Species-specific fluorophores	Minimize spectral overlap
  Chromogenic IHC	Sequential application with thorough washing	HRP/AP systems with different substrates	Complete blocking between rounds
  Chemiluminescent WB	Strip and reprobe or use different MW markers	Specific secondary antibodies	Careful stripping validation

• Pathway-relevant marker selection:

  • Upstream kinases: phospho-p38 MAPK, phospho-JNK, phospho-ERK

  • Downstream targets: ATF3, whose expression increases following ATF2 phosphorylation

  • Related transcription factors: CREB, c-Jun, c-Fos

• Sample preparation optimization:

  • Fixation conditions affect epitope preservation differently for various phospho-epitopes

  • For FFPE samples, optimize antigen retrieval conditions (pH, temperature, duration)

  • For frozen sections, fixation time dramatically impacts phospho-epitope detection

• Signal amplification strategies:

  • Tyramide signal amplification for low-abundance phospho-proteins

  • Proximity ligation assay to detect protein-protein interactions involving ATF2

  • Consider phospho-mass spectrometry for unbiased phosphorylation profiling

• Normalization approaches:

  • Total ATF2 protein levels should always be measured in parallel with phospho-ATF2

  • Use housekeeping proteins that are stable under your experimental conditions

  • Consider physiological positive controls (UV-irradiated cells) for calibration

These technical considerations ensure reliable simultaneous detection of ATF2 phosphorylation alongside other signaling components, providing a more comprehensive understanding of the signaling network.

How can ATF2 antibodies be utilized to study cancer progression mechanisms?

ATF2 antibodies offer valuable insights into cancer progression mechanisms through several research approaches:

• Tumor suppressor function assessment:

  • Recent research has demonstrated that ATF2 loss promotes tumor invasion in colorectal cancer cells by upregulating the cancer driver TROP2

  • Immunohistochemical analysis of patient samples can correlate ATF2 expression patterns with clinical outcomes

  • In vivo imaging and micro-computer tomography have verified that ATF2 knockout/TROP2 high status triggers tumor invasiveness in mouse and chicken xenograft models

• Epithelial-to-mesenchymal transition (EMT) analysis:

  • ATF2 antibodies can track changes in expression and phosphorylation during EMT

  • ATF2 loss has been associated with de-adhesion and invasion processes in colon cancer cells

  • Immunofluorescence can reveal how ATF2 status affects cellular morphology and adhesion structures

• Intratumoral heterogeneity mapping:

  • Single-cell analysis using ATF2 antibodies can identify subpopulations with different invasive potential

  • Spatial transcriptomics combined with phospho-ATF2 staining can reveal regional activation patterns

• Therapeutic response monitoring:

  • ATF2 phosphorylation states can serve as pharmacodynamic markers for drugs targeting MAPK pathways

  • In silico analysis has provided direct support that ATF2 low/TROP2 high expression status defines high-risk colorectal cancer patients

• Metastasis mechanism investigation:

  • ATF2 antibodies can be used to examine the molecular mechanisms of liver metastasis development

  • The ATF2 low/TROP2 high signature may be useful for predicting metastatic potential

These approaches demonstrate how ATF2 antibodies serve as critical tools for understanding the complex roles of ATF2 in cancer biology, particularly its context-dependent functions as a tumor suppressor in colorectal cancer.

What are the methodological approaches for investigating ATF2 in neurological research?

Given ATF2's abundance in brain tissue and its role in neuronal growth and differentiation , several methodological approaches are valuable for neurological research:

• Brain region-specific ATF2 activity mapping:

  • Immunohistochemistry with phospho-ATF2 antibodies to identify activation patterns

  • Consider tissue clearing techniques for whole-brain 3D imaging of ATF2 expression

  • Compare ATF2 phosphorylation across different neuroanatomical regions

• Stress response pathway analysis in neurons:

  • ATF2 responds to various forms of cellular stress

  • Primary neuronal cultures can be subjected to stress conditions (oxidative, excitotoxic, inflammatory)

  • Track temporal dynamics of ATF2 phosphorylation following stress induction

• Neurodevelopmental role investigation:

  • ATF2 is considered an important substrate of signals upstream of genes associated with neuronal growth and differentiation

  • Developing brain tissue can be analyzed at different embryonic and postnatal stages

  • Correlate ATF2 activation with neurogenesis and differentiation markers

• Psychiatric disorder models:

  • ATF2 expression has been linked to depression in humans

  • Animal models of depression can be analyzed for alterations in ATF2 expression/phosphorylation

  • Consider post-mortem human brain samples from patients with psychiatric conditions

• Protocol optimization for neural tissue:

  Tissue Type	Fixation Method	Antigen Retrieval	Antibody Dilution	Special Considerations
  Fresh frozen brain	Brief PFA post-fixation	Minimal or none	1:500 (IF)	Preserve phospho-epitopes
  FFPE brain sections	10% neutral buffered formalin	Citrate buffer, pH 6.0	1:50-1:100 (IHC)	Longer retrieval times
  Primary neurons	4% PFA, 10 min	Not typically needed	1:500 (IF)	Co-stain with neuronal markers
  Brain organoids	4% PFA, 30-60 min	Gentle retrieval	1:250 (IF)	Penetration challenges

These methodological approaches provide a framework for investigating ATF2's functions in neurological contexts, leveraging its known abundance in brain tissue and potential roles in neuronal processes and psychiatric conditions.

What are the critical controls for phospho-specific ATF2 antibody experiments?

For rigorous phospho-specific ATF2 antibody experiments, implement these critical controls:

• Phosphatase treatment controls:

  • Split lysate samples and treat one set with lambda phosphatase

  • This should eliminate signal from phospho-specific ATF2 antibodies

  • Confirm that total ATF2 detection remains unchanged

• Stimulus-response validation:

  • Include unstimulated samples alongside stimulated conditions

  • Known activators of ATF2 phosphorylation include:

    • UV irradiation

    • Inflammatory cytokines

    • Tolfenamic acid (which increases ATF2 phosphorylation via p38MAPK, ERK, and JNK pathways)

• Kinase inhibitor panels:

  • Pre-treat cells with specific inhibitors before stimulation:

    • p38 MAPK inhibitors (SB203580)

    • JNK inhibitors (SP600125)

    • ERK pathway inhibitors (U0126)

  • These pathway-specific inhibitors can help validate the specific kinase responsible for ATF2 phosphorylation

• Phospho-mimetic and phospho-dead mutants:

  • Compare antibody reactivity with wild-type ATF2 versus:

    • T73A (phospho-dead)

    • T73E or T73D (phospho-mimetic)

  • These constructs provide definitive controls for antibody specificity

• Cross-reactivity assessment:

  • Test antibody against related ATF/CREB family members

  • Evaluate potential cross-reactivity with other proteins containing similar phosphorylation motifs

  • The immunogen sequence (T-P-T(p)-R-F) should be checked for uniqueness to ATF2

Implementing these controls ensures the validity and specificity of results obtained with phospho-specific ATF2 antibodies in complex experimental systems.

How can I troubleshoot weak or nonspecific signals when using ATF2 (Ab-73 or 55) antibody?

When encountering weak or nonspecific signals with ATF2 (Ab-73 or 55) antibody, consider these troubleshooting strategies:

• For weak signals:

  • Optimize antibody concentration:

    • Western blot: Try narrowing the range around the recommended 1:500-1:1000 dilution

    • IHC: Test concentrations near the suggested 1:50-1:100 range

  • Enhance signal detection:

    • For WB: Use high-sensitivity ECL substrates or increase exposure time

    • For IHC/IF: Consider signal amplification systems (TSA, polymer detection)

  • Improve sample preparation:

    • Ensure robust phosphorylation by optimizing stimulation conditions

    • Add phosphatase inhibitors immediately during cell lysis

    • Minimize time between sample preparation and analysis

• For nonspecific signals:

  • Optimize blocking conditions:

    • Test different blocking agents (BSA, milk, commercial blockers)

    • Increase blocking time or concentration

  • Adjust antibody incubation parameters:

    • Reduce primary antibody concentration

    • Increase washing duration and buffer volume

    • Consider overnight incubation at 4°C instead of room temperature

  • Validate secondary antibody specificity:

    • Run secondary-only controls

    • Use highly cross-adsorbed secondary antibodies

• Technical optimization table:

  Issue	Western Blot	Immunohistochemistry	Immunofluorescence
  High background	Increase blocking (5% BSA), add 0.1% Tween-20	Reduce antibody concentration, add 0.1% Triton X-100	Use TBS instead of PBS, increase washes
  Multiple bands	Confirm lysate quality, use gradient gels	N/A	N/A
  No signal	Verify stimulation, check transfer efficiency	Optimize antigen retrieval (pH, time)	Check fixation conditions
  Weak signal	Increase protein load, reduce washing stringency	Extend DAB development time	Increase exposure time, use higher NA objectives

• Sample-specific considerations:

  • For clinical samples, optimize fixation time and processing

  • For IP-Western experiments, consider crosslinking antibodies to beads

  • For frozen sections, minimize freeze-thaw cycles and optimize fixation

These troubleshooting approaches address common challenges when working with phospho-specific antibodies like ATF2 (Ab-73 or 55), which require careful optimization to achieve specific and robust signal detection.

What are the best quantification methods for phosphorylated ATF2 across different experimental platforms?

For accurate quantification of phosphorylated ATF2 across experimental platforms:

• Western blot quantification:

  • Normalization approaches:

    • Ratio of phospho-ATF2 to total ATF2 is essential

    • Additional normalization to loading controls (GAPDH, actin)

  • Densitometry best practices:

    • Use linear range of detection (validate with dilution series)

    • Background subtraction should be consistent across samples

    • Consider specialized software (ImageJ, Image Lab, etc.)

  • Technical considerations:

    • ATF2 appears at 65-75 kDa molecular weight range

    • Both 74 kDa ATF2 protein and ~54 kDa splice forms may be detected

• Immunohistochemistry quantification:

  • Scoring systems:

    • H-score (combines intensity and percentage positive cells)

    • Digital pathology with pixel-based intensity measurement

  • Considerations:

    • Nuclear vs. cytoplasmic localization should be evaluated separately

    • Establish intensity thresholds using positive and negative controls

    • Use automated systems for unbiased assessment

• Immunofluorescence quantification:

  • Single-cell analysis approaches:

    • Nuclear to cytoplasmic ratio of phospho-ATF2

    • Correlation with other signaling markers

  • Technical parameters:

    • Z-stack acquisition for accurate nuclear signal

    • Consistent exposure settings between samples

    • Background correction using unstained regions

• Flow cytometry for phospho-ATF2:

  • Standardization:

    • Use calibration beads to normalize between experiments

    • Include stimulated vs. unstimulated controls in each run

  • Analysis metrics:

    • Median fluorescence intensity rather than mean

    • Percent positive cells above threshold

    • Consider visualizing data as histograms to capture population shifts

• Emerging technologies:

  • Mass cytometry (CyTOF) for multi-parameter analysis

  • Imaging mass cytometry for spatial context with high multiplexing

  • Digital spatial profiling for region-specific quantification

These quantification methods enable reliable measurement of phosphorylated ATF2 across diverse experimental platforms, facilitating robust comparative analyses in different research contexts.

What are the emerging applications for ATF2 antibodies in cancer research and potential therapeutic development?

ATF2 antibodies are poised to contribute significantly to cancer research and therapeutic development through several emerging applications:

• Precision medicine biomarker development:

  • Recent research has established that ATF2 low/TROP2 high expression status defines high-risk colorectal cancer patients

  • ATF2 antibodies could be used to develop clinical diagnostics for patient stratification

  • Multiplex IHC panels combining ATF2 with other markers could enhance prognostic accuracy

• Drug response prediction:

  • ATF2 phosphorylation status may predict response to kinase inhibitors

  • Monitoring phospho-ATF2 during treatment could serve as a pharmacodynamic biomarker

  • The involvement of p38MAPK, ERK, and JNK pathways in ATF2 regulation suggests potential synergies with inhibitors targeting these pathways

• Therapeutic targeting strategies:

  • Given ATF2's tumor suppressor role in colorectal cancer, approaches to restore ATF2 function might be therapeutically beneficial

  • Alternatively, in contexts where ATF2 is oncogenic, inhibiting its phosphorylation could be explored

  • TROP2 targeting might prevent the first steps in metastasis, particularly in tumors with ATF2 loss

• Intratumoral heterogeneity assessment:

  • Single-cell analysis using ATF2 antibodies could identify resistant subpopulations

  • Spatial mapping of ATF2 status within tumors might reveal invasion fronts or metastatic niches

• Circulating tumor cell characterization:

  • ATF2 status in circulating tumor cells could provide insights into metastatic potential

  • Liquid biopsy approaches incorporating ATF2 assessment might enable non-invasive monitoring

These emerging applications highlight the potential of ATF2 antibodies to contribute to cancer research beyond basic mechanistic studies, with direct implications for clinical practice and therapeutic development.

How might ATF2 research evolve with emerging technologies and methodological advances?

ATF2 research is positioned to evolve substantially with emerging technologies and methodological advances:

• Single-cell multi-omics integration:

  • Combining single-cell proteomics and transcriptomics to correlate ATF2 phosphorylation with gene expression profiles

  • Spatial transcriptomics to map ATF2-regulated gene expression in tissue context

  • Integration of phospho-proteomics with ATF2 binding sites (ChIP-seq) to create comprehensive regulatory networks

• Advanced imaging techniques:

  • Live-cell imaging of ATF2 dynamics using split fluorescent protein systems

  • Super-resolution microscopy to visualize ATF2 in nuclear subcompartments

  • Intravital microscopy to track ATF2 activation in vivo during disease progression

• CRISPR-based functional genomics:

  • CRISPRa/CRISPRi screens to identify modifiers of ATF2 function

  • Base editing to introduce specific phosphorylation site mutations

  • Prime editing for precise modeling of patient-specific ATF2 variants

• Protein interaction mapping:

  • BioID or APEX proximity labeling to identify context-specific ATF2 interaction partners

  • Hydrogen-deuterium exchange mass spectrometry to map structural changes upon phosphorylation

  • Interactome profiling across different cell types and conditions

• AI/ML applications:

  • Deep learning image analysis for automated quantification of ATF2 in complex tissues

  • Predictive modeling of ATF2 pathway activation from multi-omic data

  • Virtual screening for compounds that modulate ATF2 activity